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Background: DNA topoisomerases are key enzymes that modulate the topological state of DNA through the
breaking and rejoining of DNA strands. Human topoisomerase IB can be inhibited by several compounds that act
through different mechanisms, including clinically used drugs, such as the derivatives of the natural compound
camptothecin that reversibly bind the covalent topoisomerase-DNA complex, slowing down the religation of the
cleaved DNA strand, thus inducing cell death. Three enzyme mutations, which confer resistance to irinotecan in an
adenocarcinoma cell line, were recently identified but the molecular mechanism of resistance was unclear.
Methods: The three resistant mutants have been investigated in S. cerevisiae model system following their viability
in presence of increasing amounts of camptothecin. A systematical analysis of the different catalytic steps has been
made for one of these mutants (Glu710Gly) and has been correlated with its structural-dynamical properties studied
by classical molecular dynamics simulation.
Results: The three mutants display a different degree of camptothecin resistance in a yeast cell viability assay.
Characterization of the different steps of the catalytic cycle of the Glu710Gly mutant indicated that its resistance is
related to a high religation rate that is hardly affected by the presence of the drug. Analysis of the dynamic
properties through simulation indicate that the mutant displays a much lower degree of correlation in the motion
between the different protein domains and that the linker almost completely loses its correlation with the
C-terminal domain, containing the active site tyrosine.
Conclusions: These results indicate that a fully functional linker is required to confer camptothecin sensitivity to
topoisomerase I since the destabilization of its structural-dynamical properties is correlated to an increase of
religation rate and drug resistance.
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The integrity and the physical organization of DNA
must be maintained to ensure the survival of cells. Many
essential cellular processes can cause problems in the
topological structure of DNA. Separation of the two
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reproduction in any medium, provided the ortopological stresses that must be resolved in order to
complete DNA metabolism processes such as replica-
tion, transcription and recombination [1,2]. These prob-
lems are solved by a class of ubiquitous enzymes called
DNA topoisomerases. There are two classes of
topoisomerases (type I and type II), both characterized
by a catalytic mechanism which involves a nucleophilic
attack of a DNA phosphodiester bond by a tyrosyl resi-
due, but type I cleaves one DNA strand, whereas type II
cleaves both strands [2]. Human DNA topoisomerase IB
(hTop1) is composed of 765 amino acids, and the crystalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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together with proteolytic experiments, has shown that
the enzyme is composed of four different domains: the
N-terminal domain (residues 1–214), the core domain
(215–635), the linker domain (636–712), and the
C-terminal domain (713–765) [3-5]. Mechanistically,
hTop1 catalyzes DNA relaxation by transiently cleaving,
passing, and religating one strand of the DNA double
helix. The active site tyrosine (Tyr723) starts the cata-
lytic cycle of the enzyme through a nucleophilic attack
on the DNA backbone, resulting in the breakage of one
DNA strand with the enzyme covalently attached to the
3′-phosphate to form the cleavage complex. After chan-
ging the linking number, a second nucleophilic attack,
driven by the 5′-hydroxy DNA end, restores an intact
double-stranded DNA, and the enzyme is released [5].
Formation of the cleavage complex is a critical event
during the cell cycle since cell vitality is seriously
compromised by poisoning this complex [6]. Many small
natural and synthetic molecules target DNA topoiso-
merases [7,8]. Among these agents, camptothecin (CPT),
the most important poison of hTop1, represents the lead
compound of an important class of antitumor drugs. In
physiological conditions the DNA nicks produced by
hTop1 are rapidly sealed, while CPT can reversibly bind
to the covalent hTop1-DNA complex slowing down the
religation of the cleaved DNA strand. The stalled hTop1
complex can collide directly with the progression of the
replication fork producing lethal double strand DNA
breaks and ultimately cell death [9]. Recently, single
molecule data have hinted to a more indirect mechanism
in which the tension due to positive supercoils, gener-
ated ahead of the fork and less efficiently removed by
the ternary complex, mediate the fork collapse and for-
mation of DNA lesion [10]. Either way, CPT converts
hTop1 to a cell poison and consequently the citotoxicity
of CPT correlates directly with the intracellular hTop1
activity level. Two water-soluble CPT derivatives,
topotecan (TPT) and irinotecan (CPT-11), have been
approved by the FDA and widely used for cancer
chemotherapy. TPT is used for the treatment of
cisplatin-refractory ovarian carcinoma, and for second-
line therapy in small-cell lung cancer (SCLC). CPT-11,
with is active metabolite SN38, has been approved in the
USA for the treatment of colorectal cancer [11]. Al-
though TPT and CPT-11 have shown effectiveness in the
treatment of the above mentioned cancer types, drug re-
sistance is still a critical problem [12]. The mechanism
behind the clinical resistance to CPTs has not been fully
elucidated since selectivity and resistance towards cancer
cells are multifactorial [11-13]. Among all, the most
studied determinants of drug resistance concern hTop1
mutations with consequent reduction of cleavage com-
plexes [11,12].An important contribution toward the understanding
of the interaction of CPT with hTop1 and DNA has
been provided by the crystal 3D structure of the ternary
complex made by Topo70, corresponding to the enzyme
depleted of the N-terminal domain, covalently linked to
DNA and TPT [14,15]. The structure reveals that the
drug molecule intercalates between upstream (−1) and
downstream (+1) bp, moving the 5′-hydroxyl end away
from the scissile phosphate and thus preventing the
religation of the cleaved strand. This structure permits
to explain the CPT resistance due to mutations involving
residues that interact directly with the drug or that alter
the interaction with DNA [16]. However, it is not able to
explain the CPT resistance for point mutations involving
residues not directly contacting the drug. In this case an
explanation has been provided by a series of works com-
bining in vitro activity assays and molecular dynamics
(MD) simulation [16-19]. These works have shown that
a common feature of these CPT resistant mutants is the
presence of an anomalous linker mobility and/or a loss
of interdomains correlated motion between the linker
domain and the C-terminal domain containing the cata-
lytic tyrosine 723. The importance of the linker in
modulating the CPT sensitivity has been firstly demon-
strated by its deletion that gives rise to an enzyme that
has an increased religation rate and is partially CPT
resistant [20]. The linker-deleted enzyme also loses the
correlation between the various protein domains as de-
monstrated by MD simulations [21]. A connection be-
tween the presence of the drug and linker mobility has
been confirmed by the simulation of the hTop1-DNA-TPT
ternary complex showing that the presence of the drug
reduces the linker mobility [22] a result confirmed by
the simulation of the hTop1-DNA-indenoisoquinoline
ternary complex [23]. In line the 3D structure of the
ternary complex shows a well defined electron density
for the linker domain that is not observed for the
DNA-topo70 binary complex crystallized in the same
conditions [4,5].
In a recent report new hTop1 mutations which con-
fer resistance to irinotecan in a adenocarcinoma cell
line have been identified [24]. These mutations are lo-
cated in helix 17 of the core subdomain III (Arg621His
and Leu617Ile) and at the end of helix 19 of the linker
domain (Glu710Gly). The arginine 621 and the glutam-
mic acid 710 interact together via a salt bridge and
form part of the interface between helices 17 and 19.
Arg621His and Glu710Gly are found in moderately re-
sistant clones, whereas Leu617Ile mutation is found
in highly resistant clones that also over-express the
ABCG2 transporter, so that in this latter case the re-
sistance is also due to the elimination of the drug by
the efflux pumps [24]. The authors suggest that the
resistance is likely due to an altered hTop1 linker
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hypothesis.
In the present paper we have produced Arg621His,
Glu710Gly and Leu617Ile mutants and confirmed their
CPT sensitivity in a yeast cell viability assay. Due to our
experience and interest in the characterization of drug re-
sistant mutants involving residues localized in the linker
domain, we then focused our research on the purified
Glu710Gly mutant in order to find a molecular explan-
ation for its resistance. Through a combined experimental
and simulative approach, we provide evidence that the
CPT resistance of the mutant is due to a fast religation
rate coupled to a loss of correlation between the linker
and the C-terminal domain confirming the crucial role of
the linker domain in controlling hTop1 drug sensitivity.
Results
Glu710Gly mutant is resistant to CPT in vivo and in vitro
The mutations (Leu617Ile, Arg621His and Glu710Gly)
found in the CPT-11 resistant HCT116 clones by Gongora
et al. [24] have been introduced in the single copy yeast
plasmid (YCp) expressing hTopI under the GAL1 pro-
moter. To assess the in vivo consequences of mutants ex-
pression, the viability and CPT sensitivity of Top1Δ yeast
cells (EKY3), transformed with GAL1-hTop1 constructs,Figure 1 CPT sensitivity in vivo and in vitro. (A) Exponentially growing y
Leu617Ile, Arg621His, Glu710Gly, wild type and vector have been serially 10
dextrose, of galactose (Gal), or of galactose plus the indicated CPT concent
experiment for the wild type and the Glu710Gly mutant in presence of DM
control (C) where no protein added. The reaction products are resolved in
of the supercoiled plasmid DNA are indicated as “Dimer” and “Monomer”.have been tested. The expression vector carries the Ura-
selectable marker and is maintained by selection in syn-
thetic complete SC Ura-medium. At least five independent
clones were selected from each transformation. Serial dilu-
tions of yeast cells, transformed with the indicated plas-
mids, have been spotted on plates containing dextrose or
galactose, supplemented with different CPT concentra-
tions, to assess drug sensitivity following the yeast growth.
The data show that yeast cells expressing the wild type
protein exhibit a deficiency in viability in the presence of
10 ng/ml CPT, while the three mutations render the
enzyme resistant to CPT (Figure 1A). However, the mu-
tants display a different sensitivity to CPT concentration:
Arg621His and Glu710Gly produce viable colonies until
100 ng/ml of CPT while the Leu617Ile is less resistant
growing only up to 50 ng/ml.
The effect of 60 μM CPT on the ability of wild type and
Glu710Gly enzymes to mediate relaxation of supercoiled
plasmid, under standard assay conditions, has been
assessed incubating 18 ng of each enzyme with 0.5 μg of a
negative supercoiled plasmid in a time course kinetics
from 0.25 to 30 minutes. Since CPT is dissolved in di-
methyl sulfoxide (DMSO), an assay of the enzyme activity
in the presence of an identical amount of DMSO without
CPT has been also carried out, to show that DMSO doeseast cells transformed with a single copy plasmid expressing
-fold diluted and spotted onto selective media in the presence of
rations. (B) Relaxation of negative supercoiled plasmid in a time course
SO (lanes 1–9) and 100μM CPT (lanes 10–18); lane 19 represents the
an agarose gel and visualized with ethidium bromide. The two forms
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tions have been stopped and the products resolved by
agarose gel electrophoresis. As shown in Figure 1B, the
two enzymes exhibit comparable relaxation activities,
since they completely relax the supercoiled DNA after
0.5 minutes of incubation (Figure 1B, lanes 2). The pres-
ence of CPT considerably slows down the relaxation of na-
tive hTop1, a full relaxation being observed only after
about 8 minutes from the drug addiction (Figure 1B,
lane17). On the other hand the Glu710Gly mutant com-
pletely relaxes the supercoiled DNA in 1–2 min in pres-
ence of the drug (Figure 1B lane 13–14), confirming its
CPT resistance. The same experiment has been carried
out using a more diluted enzyme, confirming that the re-
laxation rate for the wild type and mutant is comparable
and that the mutant is CPT resistant (data not shown).
The resistance of the Glu710Gly has been analyzed in de-
tail following the different steps of the catalytic cycle and
studying its structural and dynamical properties by MD
simulation.
Kinetics of cleavage of the wild type and
Glu710Gly mutant
The time course of the cleavage of the wild type and
Glu710Gly mutant has been followed using a suicide cleav-
age substrate. In detail, a 5′-end radiolabeled oligonu-
cleotide CL14 (5′-GAAAAAAGACTTAG-3′) has been
annealed to the CP25 (5′-TAAAAATTTTTCTAAGTCT
TTTTTC-3′) complementary strand, to produce a duplex
with an 11-base 5′-single-strand extension. The enzyme
preferentially cuts at the site indicated by the arrow, as
shown in top of Figure 2A. Using this substrate the
religation step is almost totally precluded, because the AG-
3′ is too short to be religated, leaving the enzyme cova-
lently attached to the 12 oligonucleotide 3′-end [17]. For a
suicide substrate incubated with an excess of wild type or
mutant enzyme, the cleaved DNA fragments have been re-
solved in a time course experiment in a denaturing poly-
acrylamide gel as reported in Figure 2A. The amount of
fragment, normalized to the maximum value of the wild
type protein, plotted as a function of time in Figure 2B, sug-
gests that both enzymes have an almost identical cleavage
rate (kcl), being the initial part of the curves almost identical
in both reactions. The two enzymes however don’t reach
the same plateau value leaving us with the hypothesis that
a small amount of AG-3′ could be religated and that the
mutant could religate this short oligonucleotide faster than
the wild type enzyme. In order to address this hypothesis
a different cleavage substrate has been used to follow the
rate of cleavage. In detail, a 5′-end radiolabeled oligo-
nucleotide, named CL14-U (5′-GAAAAAAGACTUAG-
3′), having the deoxyribo-thymine (dT) in position 12
substituted with a ribo-Uracil (rU), has been annealed to
the CP25 (5′-TAAAAATTTTTCTAAGTCTTTTTTC-3′)complementary strand, to produce a duplex with an
11-base 5′-single-strand extension. With this substrate,
when the enzyme cuts at the preferential site indicated by
an arrow at the top of Figure 3A, the 2′-OH of the ribose
attacks the 3′-phosphotyrosyl linkage between the enzyme
and ribonucleotide, releasing hTop1 and leaving a 2′,3′-
cyclic phosphate end [25]. In this way the enzyme is not
anymore covalently linked to the substrate and the short
oligonucleotide cannot be religated. The wild type and the
mutant have been incubated with the substrate and the
fragments have been resolved in a time course experi-
ment in a denaturing polyacrylamide gel and the result
is reported in Figure 3A. The cleaved oligo (CL1 in
Figure 3A) runs like a 12 mer since no protein is attached
to it and the plot of the amount of this fragment as a func-
tion of time, normalized to the maximum value of the wild
type protein, unambiguously demonstrates that the wild
type protein and the Glu710Gly mutant have the same
rate of cleavage and reach the same plateau value
(Figure 3B).Kinetics of religation of the wild type and Glu710Gly
mutant
The DNA religation step has been studied by testing the
ability of both enzymes to religate the oligonucleotide R11
(5′-AGAAAAATTTT-3′) in the presence or absence of
CPT, added to the cleavage complex obtained incubating
the suicide substrate with an excess of enzyme. Aliquots
have been removed at different times, the reaction stopped
by addition of SDS and the products analyzed by poly-
acrylamide gel electrophoresis (Figure 4A). The percent-
age of the remaining covalent complex (CL1), normalized
to the value at t=0 is plotted, as a function of time, in
Figure 4B. The data show that the Glu710Gly mutant has
a higher religation rate when compared with the wild type
enzyme (Figure 4A, compare lanes 2–6 with lanes 11–15).
The presence of CPT strongly decreases the religation rate
in the wild type protein (lanes 7–10), whereas has only a
small effect for the Glu710Gly mutant (lanes 16–19)
bringing the religation rate to a value similar to the one
observed for the wild type in absence of the drug, as
shown by the quantitative plot of Figure 4B.MD simulation
Root mean square displacement (RMSD) plots along the
75 ns simulation of the native and mutated proteins
show that in both proteins the core is stable (see
Additional file 1) and that the largest deviation is due to
the linker domain. This is confirmed by the root mean
square fluctuations (RMSF), where the larger contribu-
tion comes from the linker domain (Figure 5). The two
systems show comparable values along the sequence, ex-
cept for the peaks at 466–471 and 608–610 that have
Figure 2 Cleavage kinetics. (A) Time course (0.25-30 minutes) of the cleavage reaction between the CL14/CP25 suicide substrate, shown at the
top of the figure and the purified wild type (lanes 1–9), and Glu710Gly mutant (lanes 10–18). In lane 19 the protein has not been added. CL1
represents the DNA strand cleaved by the enzymes at the preferred cleavage site, indicated by an arrow. (B) Percentage of cleaved suicide
substrate, normalized to the maximum value of the wild type, plotted against time for the reaction with wild type (black) and Glu710Gly mutant
(grey). Data shown are means ± SD from 3 independent experiments.
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higher values in the wild type.
Local impact of mutation
In the X-ray structures [5,15,26] helix 19 (residues 679–
710, one of the two helices of the linker domain), dir-
ectly faces helix 17 (residues 612–629), through two salt
bridges (Glu710-Arg621 and Asp707-Arg624) permitting
the communication between the linker domain and the
cap-core structure of the protein (Figure 6A). In the wild
type simulation the side chains of these residues keep
forming a network of salt bridges for a large percentageof time (85% and 96%) as shown in Figure 6C, left side,
where a representative snapshot of the simulation is
shown. In the simulation of the Glu710Gly mutant, be-
sides the obvious disappearance of the Glu710-Arg621
salt bridge, the Asp707-Arg624 salt bridge is also broken
(only 9% existence), thus separating the communication
between the base of the linker with the core of the pro-
tein (Figure 6C, right side). Another effect of the muta-
tion is observed in the bundle of helices (16, 17 and 21)
neighbouring the mutation zone, (see Figure 6A), where
helices 16 and 21 change their relative orientation since
Trp732, located on helix 21, interacts with Thr605 in the
Figure 3 Cleavage kinetics using ribo-modified substrate. (A) Time course (0.25-60 minutes) of the cleavage reaction of purified wild type
(lanes 1–8), and Glu710Gly mutant (lanes 9–16) with the CL14-U/CP25 substrate (shown at the top of the figure). In lane 17 the protein has not
been added. CL1 represents the DNA strand cleaved by the enzymes at the preferred cleavage site, indicated by an arrow at the top of the
figure. (B) Percentage of cleaved substrate, normalized to the maximum value of the wild type, plotted against time for the reaction with wild
type (black diamond’s) and with Glu710Gly mutant (grey squares). Data shown are means ± SD from 3 independent experiments.
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shown by two representative snapshots of the simula-
tions in Figure 6B. As a consequence the C-terminal of
helix 16, downstream of this interaction increases its
flexibility explaining the peak seen in the RMSF for resi-
dues 607–610 (Figure 5).
Global motion
The Glu710Gly mutation has an important effect on the
concerted motions of the protein as can be noted compar-
ing the dynamic cross-correlation matrix of the C-alpha
atoms of the protein residues during the trajectories of the
wild type and the mutant (Figure 7, top and bottom halvesrespectively). In the figure the pairs of Cα atoms charac-
terized by strong correlated motions are represented by a
pixel of red, yellow or green color, while anticorrelated
motions are shown in cyan, blue and violet. The mutant
is endowed with a much lower degree of correlation.
In detail, in the wild type, the linker has a strong
anticorrelated motion with the C-teminal domain and
the C-terminal region of subdomain III (squares in
Figure 7) and a lower, but still pronounced, anti-
correlated motion with the nose cone helices (repre-
senting the protein region that contacts the DNA on
the opposite side respect to the linker, downstream of
the cleavage site, circled in Figure 7). In the mutant
Figure 4 Religation kinetics. (A) Gel analysis of the religation kinetics observed when incubating the wild type or the Glu710Gly mutant-suicide
cleavage complex with the R11 complementary ligator oligonucleotide (shown at the top of the figure) in absence [lanes 3–6 and lanes 12–15
for wild type and Glu710Gly mutant respectively] or in presence of 100 μM CPT [lanes 7–10 for the wild type and lanes 16–19 for the Glu710Gly
mutant]. In lane 1 no protein was added. The lanes 2 and 11 represent the time 0 for the wild type and the Glu710Gly mutant reactions, before
the addition of the complementary R11 strand. “CL1” represents the DNA fragment cleaved at the preferred enzyme site; “religation” is the
restored fully duplex oligonucleotide representing the final product of the religation reaction. (B) Plot of the percentage of disappearance of the
cleavage complex relative to time 0, in absence or in presence of CPT for the wild type (triangles, full and dashed black lines, respectively) and
the Glu710Gly mutant (squares full and dashed grey lines, respectively). Data shown are means ± SD from 3 independent experiments.
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ened (Figure 7 bottom). A similar loss of correlation has
been found for the Thr729Lys that also displays CPT
resistance [18].Discussion
In this study we have characterized three hTop1 mutants,
Leu617Ile, Arg621Lys and Glu710Gly, found to be in-
volved in the cytotoxicity mechanisms of CPT-11 in colon
Figure 5 Root mean square fluctuation of the protein residues during the MD trajectory. Black line represents the wild type and the red
one the mutant. The various domains of the protein are indicated for sake of clarity.
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cells, where the endogenous Top1 has been deleted and
the hTop1 with its specific mutations has been inserted,
indicates that the cells are able to grow also in presence of
CPT (Figure 1A), confirming the CPT resistance of the
three mutants. Arg621Lys and Glu710Gly display a CPT
resistance higher than Leu617Ile mutant (Figure 1A) while
in the results observed in colon cancer cells Arg621Lys
and Glu710Gly are found in the moderately resistantFigure 6 Protein structure and representative interactions that chang
tube, DNA strand in green and helices of interest are depicted as ribbons:
red, helix 21 in yellow. (B) A closeup of the representative snapshots of the
(C) Same as B but closeup on the interactions between helix 17 and helixclones, and Leu617Ile mutant in highly resistant clones
[24]. These apparent contradictory results can be ex-
plained considering that this latter clone is also over-
expressing the ABCG2 pump, so that part of the
resistance is due to the expulsion of the drug by the
pump, whilst for the other two clones the resistance is
only due to the hTop1 mutations.
Characterization of the different steps of the catalytic
cycle of the Glu710Gly mutant permits to understande during the simulations. (A) View of the protein depicted as a gray
helices 18 and 19 (linker domain) in orange, helix 16 in blue, helix 17 in
simulations depicting the interactions between helix 16 and helix 21.
19.
Figure 7 Dynamic cross correlation maps between Cα atoms, of the wild type and mutated protein. Top left triangle represents the wild
type, bottom right represents the Glu710Gly mutant. Subdomain decomposition is also indicated. Color coding for the correlation values is given
on the bottom, negative values indicate anticorrelation, positive ones indicate direct correlation. Regions of interest are enclosed in blue
rectangles and circles.
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rate comparable to the wild type but addition of CPT
only partially affects its relaxation at variance on what
observed on the wild type (Figure 1B lane 10–18). The
mutant and the wild type have a comparable cleavage rate.
However when a suicide substrate is used they reach
different plateau values, being lower for the mutant
(Figure 2). This result can be interpreted considering that
the mutant has a cleavage rate identical to the wild type
but it is characterized by a faster religation rate, that al-
lows the mutant to rapidly religate the dinucleotide lower-
ing its plateau. In line with this hypothesis using a
different cleavage substrate having a ribonucleotide in
the −1 position, wild type and mutant not only have the
same rate but also reach an identical plateau (Figure 3).
With this substrate the detachment of the protein from
the cleavage complex is not carried out by the 5′-OH of
the dinucleotide but by the 2′-OH of the ribose moiety inposition −1, and this detachment is likely happening with
the same efficiency for the two enzymes [25].
The large rate of the mutant in religation is demon-
strated by the experiment in Figure 4 where it is shown
that the complementary strand added to the cleavage
complex is bound by the mutant at least twice faster
than the wild type. Moreover addition of CPT only
slightly reduces the mutant religation rate, that in pres-
ence of the drug reaches a value comparable to the one
observed for the wild type in absence of CPT (Figure 4).
The increase in religation rate is correlated to a change
in the structural-dynamical properties of the enzyme as
studied by MD simulation. The mutant is in fact charac-
terized by a much lower degree of correlation of the pro-
tein domain motions when compared to the wild type.
In detail, the large correlation observed in the wild type
between the linker domain and the C-terminal domain,
the C-terminal region of subdomain III and the nose cone
Tesauro et al. Molecular Cancer 2013, 12:100 Page 10 of 13
http://www.molecular-cancer.com/content/12/1/100helices is almost completely lost in the mutant (Figure 7).
This result is likely due to the breaking of a direct commu-
nication between the linker domain and the core of the
protein due to a loss of two salt bridges (Figure 6). Follow-
ing these data the linker and the active site, located in the
C-terminal domain, must have an anticorrelated motion
to have a full control of the religation rate. It is interesting
that a similar behavior has been observed for another sin-
gle CPT resistant mutant where Thr729 has been mutated
to Lys [27]. Also in this case a disabled linker not having
an anticorrelated motion with the C-terminal domain and
the C-teminal region of the core domain produced CPT
resistance and an increased religation rate, confirming the
important role of the linker domain in tuning the
religation process.
The importance of the linker in modulating the enzyme
function has been firstly demonstrated studying the en-
zyme deleted of the linker that displays an increase of the
religation rate and a decrease in CPT sensitivity [20]. In a
series of works concerning single and double mutants
(e.g. Ala653Pro, Lys681Ala, Asp677Gly-Val703Ile) we have
shown that there is a correlation between linker flexibility
and CPT reactivity [16,17,28] a large flexibility being asso-
ciated to CPT resistance. Such a correlation has been re-
cently confirmed from a chimeric enzyme constituted by
the human enzyme containing a linker from P. falciparum
Top1 [29]. The chimeric enzyme has a linker displaying a
large flexibility and it is CPT resistant. In this work we
show that not only an increased flexibility but also a loss
of the linker correlated motions produce an increased
religation rate and CPT resistance, as also found for the
Thr729Lys mutant [27]. CPT has been proposed not only
to interfere with religation but also to slow down the
uncoiling rate [10]. This effect is seen only in presence of
a fully functional linker and so the loss of linker correlated
motions observed in the here studied mutant could be re-
lated to CPT resistance trough its incapability in slowing
down the uncoiling rate as observed in single molecule ex-
periments [10,30].
Taken together all these works point out the crucial role
of the linker in modulating and controlling the enzyme ca-
talysis and in particular the religation step and confirm
that, any time we have a disabled linker, either through a
large flexibility or via a loss of correlated motions with
other domains and in particular with the C-terminal do-
main containing the active site, a direct effect on the cata-
lytic rate and then on the CPT reactivity is found.Materials and methods
Chemicals, yeast strains and plasmids
DMSO and CPT were purchased from Sigma-Aldrich.
CPT was dissolved in 99.9% DMSO to a final concentra-
tion of 4 mg/ml (11.5 mM) and stored at −20°C.ANTI-FLAG M2 monoclonal affinity gel, FLAG pep-
tide and ANTI-FLAG M2 monoclonal antibody were
purchased from Sigma-Aldrich.
Saccharomyces cerevisiae top1 null strain EKY3 (ura3-52,
his3Δ200, leu2Δ1, trp1Δ63, top1:TRP1, MATα) previously
described [31] was used to express the hTop1 gene.
YCpGAL1-e-hTop1 single copy plasmid was described pre-
viously [31,32]. Leu617Ile, Arg621His and Glu710Gly were
generated by oligonucleotide-directed mutagenesis of the
YCpGAL1-wild type in which the human topoisomerase I
is expressed under the galactose inducible promoter in a
single-copy plasmid. The epitope-tagged construct YCp
GAL1-e-wild type contains the N-terminal sequence FLAG:
DYKDDDY (indicated with ‘e’), recognized by the M2
monoclonal antibody. The epitope-tag was subcloned into
YCpGAL1-hTop1Leu617Ile, YCpGAL1-hTop1Arg621His
and YCpGAL1-hTop1Glu710Gly to produce the YCpG
AL1-e-hTop1Leu617Ile, YCpGAL1-e-hTop1Arg621His and
YCpGAL1-e-hTop1Glu710Gly construct. The cloning reac-
tions were transformed into XL10-Gold E. coli cells
(Agilent Technologies) and positive clones were identified
by sequencing the extracted plasmid DNA.
Drug sensitivity assay
Yeast EKY3 strains were transformed with YCp50,
YCpGAL1-e-hTop1, YCpGAL1-e-hTop1Leu617Ile, YC
pGAL1-e-hTop1Arg621His and YCpGAL1-e-hTop1
Glu710Gly vectors by LiOAc treatment [33] and se-
lected on synthetic complete (SC)-uracil medium supp-
lemented with 2% dextrose. Transformants were grown
to an A595=0.3 and 5 μl aliquots of serial 10-fold dilu-
tions were spotted onto SC-uracil plates plus 2% dex-
trose or 2% galactose, with or without the indicated
concentrations of CPT.
HTop1 and hTop1Glu710Gly purification
EKY3 yeast cells, transformed with the YCpGAL1-e-hTop1
and YCpGAL1-e-hTop1Glu710Gly were grown over-
night on SC-uracil plus 2% dextrose, at an optical dens-
ity of A595=1.0 they were diluted 1:100 in SC-uracil plus
2% raffinose. At an optical density of A595=1.0, the
cells were induced with 2% galactose for 6 h. Cells were
then centrifuged, washed with cold water and re-
suspended in 2 ml buffer/g cells (50 mM Tris–HCl, pH
7.4, 1 mM EDTA, 1 mM EGTA, 10% glycerol and prote-
ase inhibitors cocktail from Roche, supplemented with
0.1 mg/ml sodium bisulfate, 0.8 mg/ml sodium fluoride,
1mM Phenylmethanesulfonylfluoride (PMSF) and 1mM
DTT). After addition of 0.5 volumes of 425–600 μm
diameter glass beads, the cells were disrupted by
vortexing for 30 seconds alternating with 30 seconds on
ice and then were centrifuged at 15000g for 30 minutes.
For homogenous protein preparations, the whole ex-
tracts were applied to an ANTI-FLAG M2 affinity gel
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the manufacturer protocol. Then, columns were washed
with 20 volumes of TBS (50 mM Tris–HCl pH 7.4 and
150 mM KCl) supplemented with the protease inhi-
bitors, prior to load the lysate. Elution of e-hTop1, or
e-hTop1Glu710Gly, was performed by competition with
five column volumes of a solution containing 1mg of
FLAG peptide (DTKDDDDK) in TBS. Fractions of 500 μl
were collected and 40% glycerol was added in all prepara-
tions, which were stored at −20°C [17]. Protein levels and
integrity were assessed by immunoblot with the monoclo-
nal anti M2 antibody (Sigma-Aldrich). The hTop1 and
hTop1Glu710Gly similar concentrated fractions were also
compared to the purified hTop1 with a known concentra-
tion (provided from Topogene) by immunoblot using the
ab58313 Anti-Top1 antibody (Abcam) and ab97240 goat
polyclonal Secondary Antibody (Abcam). The relative
concentration of the two chosen fractions was estimated
by a densitometry quantification using ImageJ software
[34]. The in vitro experiments have been performed using
equal amount of purified hTop1 and hTop1Glu710Gly.
DNA relaxation assays
The activity of 1 μl of hTop1 (16ng/μl) or hTop1Glu710Gly
(16ng/μl) was assayed in 30 μl of reaction volume con-
taining 0.5 μg of negatively supercoiled pBlue-Script KSII
(+) DNA, that is present in both dimeric and monomeric
forms and reaction buffer (20 mM Tris–HCl pH 7.5,
0.1 mM Na2EDTA, 10 mM MgCl2, 5 μg/ml acetylated bo-
vine serum albumin and 150 mM KCl).
The effect of CPT on enzyme activity was measured
by adding DMSO or 100μM of the drug to the reactions,
that were stopped with 0.5% SDS after each time-course
point at 37°C. The samples were resolved in a 1% (w/v)
agarose gel in 48 mM Tris, 45.5 mM boric acid, 1 mM
EDTA at 10 V/cm. The gels were stained with ethidium
bromide (0.5 μg/ml), destained with water and
photographed using a UV transilluminator.
Cleavage kinetics
Oligonucleotide CL14 (5′-GAAAAAAGACTTAG-3′)
that contain a hTop1 high affinity cleavage site, was 5′-
end labelled with [γ32P] ATP. The CP25 complementary
strand (5′-TAAAAATTTTTCTAAGTCTTTTTTC-3′)
was 5′-end phosphorylated with unlabeled ATP. The
two strands were annealed with a 2-fold molar excess of
CP25 over CL14 [35]. The suicide cleavage reactions
were carried out by incubating 20 nM of the duplex
DNA with an excess of hTop1 or hTop1Glu710Gly en-
zymes at 25°C, in 20 mM Tris–HCl pH 7.5, 0.1 mM
Na2EDTA, 10 mM MgCl2, 5 μg/ml acetylated BSA, and
150 mM KCl, in a final volume of 50 μl [36]. At various
time points 5 μl aliquots were removed and the reaction
stopped with 0.5% (w/v) SDS. After ethanol precipitationsamples were resuspended in 5 μl of 1 mg/ml trypsin
and incubated at 37°C for 60 minutes. However a short
trypsin resistant peptide is always left explaining why the
CL1 migrates slower than the CL14 oligonucleotide [20].
Samples have been analyzed by denaturing 7 M urea/20%
polyacrylamide gel electrophoresis in TBE (48 mM Tris,
45.5 mM Boric Acid, 1 mM EDTA).
Oligonucleotide CL14-U (5′-GAAAAAAGACTUAG-
3′) was 5′ end labelled and annealed with CP25 as for
the CL14. 20 nM substrate has been incubated with an
excess of hTop1 or hTop1Glu710Gly enzymes in 20 mM
Tris–HCl pH 7.5, 0.1 mM Na2EDTA, 10 mM MgCl2,
5 μg/ml acetylated BSA, 150 mM KCl, at 25°C in a final
volume of 40 μl. At various time points 5 μl aliquots
were removed and the reaction stopped with 0.5% (w/v)
SDS and directly loaded without ethanol precipitation
and trypsin digestion. Samples have been analyzed by
denaturing 7 M urea/20% polyacrylamide gel electro-
phoresis in TBE (48 mM Tris, 45.5 mM Boric Acid, 1
mM EDTA). In both experiments the percentage of
cleaved substrate (CL1) was determined by Phosphor-
Imager and ImageQuant software and normalized on the
total amount of radioactivity in each lane.
Religation kinetics
20 nM of CL14/CP25 (radiolabeled as previously de-
scribed in the cleavage kinetic experiment) was incu-
bated with an excess of hTop1 or hTop1Glu710Gly for
60 minutes at 25°C followed by 30 minutes at 37°C in
20 mM Tris–HCl pH 7.5, 0.1 mM Na2EDTA, 10 mM
MgCl2, 50 μg/ml acetylated BSA, and 150 mM KCl.
After the formation of the cleavage complex (CL1) a 5μl
aliquote was removed and used as time 0 point, then
DMSO or 100 μM CPT were added and religation reac-
tion was started by adding a 200-fold molar excess of
R11 oligonucleotide (5′-AGAAAAATTTT-3′) over the
CL14/CP25 [20]. 5 μl aliquots were removed at various
time points, and the reaction stopped with 0.5% SDS.
After ethanol precipitation, samples were resuspended in 5
μl of 1 mg/ml trypsin and incubated at 37°C for 60 mi-
nutes. Samples were analyzed by denaturing 7 M urea/20%
polyacrylamide gel electrophoresis in 48 mM Tris,
45.5 mM Boric Acid, 1 mM EDTA. The percentage of
remaining cleavage complex was quantified by Image-
Quant software, normalized to the total radioactivity for
each lane and to the value at t=0 and finally plotted as a
function of time.
Molecular dynamics
The initial configuration of the wild type hTop1, in cova-
lent complex with a 22 base pair linear double helix
DNA substrate, has been modeled from the crystallo-
graphic structures (PDB 1K4S and 1TL8, respectively) as
already reported [23].
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mer module presents in the Chimera package [37]. The
systems have been modeled using the AMBER03 all-
atom force field [38] implemented by Sorin and Pande
[39] in the GROMACS MD package version 4.5.4 [40].
The proteins was placed in a rhombic dodecahedron box
with a minimum distance of 14 Å from the box edges,
then filled with water molecules described by means of
the TIP3P rigid potential and Na+ counter-ions [41] were
added to neutralize DNA-enzyme total charge via the
genion tool of the GROMACS package. The resulting WT
system is composed of 9456 protein atoms, 1400 DNA
atoms, 58919 water molecules, 20 Na+ ions, for a total of
187633 atoms.
Particle Mesh Ewald method (PME) was used to han-
dle long-range electrostatic interactions using a cutoff of
1.2 nm in real space and the same cutoff value was used
for Van der Waals interactions [42]. The LINCS algo-
rithm was used to constrain bond lengths and angles
[43]. Relaxation of solvent molecules and Na+ ions was
initially performed keeping solute atoms restrained to
their initial positions, in three cycles with decreasing
force constant of 1000, 600 and 300 kJ/(mol N nm), for
300 ps each. The two systems have then been simulated
for 75 ns with a time step of 2.0 fs and the neighbor list
was updated every 10 steps. Temperature was kept con-
stant at 300 K using the velocity rescale Berendsen
method with a coupling constant of 0.1 ps during sam-
pling, while pressure was kept constant at 1 bar using
the Parrinello-Rahman barostat with a coupling constant
of 1.0 ps during sampling [44].
Standard analyses, as root mean square deviations
(RMSD) and fluctuations (RMSF), hydrogen bonds, dis-
tances evaluations etc. were calculated using tools of
GROMACS MD 4.5.3 [40] package. Correlation maps
were calculated on the C-alpha atoms as described [18]
with in-house written codes. Images were produced with
VMD [45] and Chimera [37].Additional file
Additional file 1: RMSD. Root mean square deviation from the starting
structure for wild type and Glu710Gly mutant. Plots were calculated for
the core of the protein (black and green lines) and the whole protein
including the linker (red and blue lines) for wild type and mutant
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